- Subject who has been on an anti-TNFα agent must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months or have been intolerant to at least 1 administration of an anti-tumor necrosis factor alpha (TNFα) agent. Subjects may not have been on more than 1 anti-TNFα agent.